Market Analysis: Global Hospital-Treated Gram-Negative Infections Market

Global hospital-treated gram-negative infections market is expected to register a substantial CAGR in the forecast period of 2019-2026. The report contains data from the base year of 2018 and the historic year of 2017. This rise in market value can be attributed to the continuous research and development of various pharmaceutical organizations.

Key Market Competitors:

Few of the major competitors currently working in the global hospital-treated gram-negative infections market are Merck & Co., Inc.; Pfizer Inc.; Lupin Pharmaceuticals, Inc.; Istituto Lusofarmaco D’Italia S.p.A.; Adelco; Achaogen, Inc.; ALLERGAN; MELINTA THERAPEUTICS, INC.; Polyphor Ltd.; Shionogi Inc.; Tetraphase Pharmaceuticals; Spero Therapeutics; AiCuris GmbH & Co. KG; Allecra Therapeutics; SUMMIT THERAPEUTICS PLC; Curza; Boston Pharmaceuticals and Nabriva Therapeutics plc among others.

Market Definition: Global Hospital-Treated Gram-Negative Infections Market

Hospital-treated gram-negative infections are microbial infections caused by different pathogens interacting with the patient’s bloodstream through wounds, surgical sites and other areas in a healthcare setting. These infections are caused by various pathogens with the most common, “klebsiella”, “E.coli”, “Acinetobacter” and various others.

Patients suffering from gram negative infections are known to have high fever, lack of appetite, nausea and in some extreme cases even seizures. Their treatment and removal is achieved with the help of combination of different therapeutics and systems inclusive of regular controlled dosage of anti-microbials with anti-biotics.

Market Drivers

Increasing rate and prevalence of antibiotic resistance is expected to boost the growth of the market
Lack of effectiveness in treating of these anti-microbial infections with the help of traditional therapeutics is expected to boost the growth of the market
Growing mortality rate caused by anti-microbial resistance is giving rise to better therapeutic solutions; this factor is expected to drive the growth of the market

Market Restraints

Lack in the availability of anti-microbial agents in the form of pharmaceuticals or drug pipeline for the treatment of gram-negative infections; this factor is expected to restrict the growth of the market
Significant numbers of resistance and challenges facing the companies and pharmaceuticals regarding the development of treatment solutions; this factor is expected to restrict the growth of the market

Get Sample Analysis of Global Market Information: https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-hospital-treated-gram-negative-infections-market

Segmentation: Global Hospital-Treated Gram-Negative Infections Market

By Therapy

Cephalosporin, Aminoglycoside
Ampicillin/Sulbactam, Carbapenem, Colistin or Rifampin
Aminoglycoside, Carbapenem, Colistin, Fosfomycin, Rifampin, or Tigecycline
Ceftolozane/Tazobactam
Ceftazidime/Avibactam
Others

By Indication

NP
cSSSIs/SSIs
BSIs
cIAIs
UTIs

By Pathogen Type

Klebsiella
Acinetobacter
Coli
Cepacia
Pseudomonas
Serratia
Enterobacter
Others

By Application

Hospitals
Labs

By Geography

North America
U.S.
Canada
Mexico
Europe
Germany
Italy
U.K.
France
Spain
Netherlands
Belgium
Switzerland
Turkey
Russia
Rest of Europe
Asia-Pacific
Japan
China
India
South Korea
Australia
Singapore
Malaysia
Thailand
Indonesia
Philippines
Rest of Asia-Pacific
South America
Brazil
Rest of South America
Middle East and Africa
South Africa
Rest of Middle East and Africa

Get TOC of Full Report: https://www.databridgemarketresearch.com/toc/?dbmr=global-hospital-treated-gram-negative-infections-market

Key Developments in the Market:

In June 2019, MELINTA THERAPEUTICS, INC. announced that the US FDA had accepted the company’s supplemental NDA (sNDA) for “BAXDELA (delafloxacin)” for priority review. The application will expand the current indication application for adults with community-acquired bacterial pneumonia (CABP). This approval is based on positive results out of Phase III study
In October 2018, Novartis AG announced that they had agreed with Boston Pharmaceuticals for the development of anti-infective drug candidates included in “Novartis Infectious Diseases” portfolio. These candidates will be designed for treatment of anti-biotic resistance such as “gram-negative infections”. This agreement will provide Boston Pharmaceuticals worldwide rights, wherein Novartis will receive financial payments upfront as well as in royalties and milestone achievements

Competitive Analysis:

Global hospital-treated gram-negative infections market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of hospital-treated gram-negative infections market for global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.